Exclusion Criteria:~1. Any other central nervous system (CNS) disease that would be expected to affect
cognition, Parkinson's disease, multiple sclerosis.~2. Any history of brain injury (e.g., concussion with
significant loss of consciousness)~3. Any significant systemic illness or unstable medical condition~4. Current
use of Parkinson's medications, antipsychotic medications, anti-seizure medications, or anticholinergic
medications~5. Current or lifetime diagnosis of a schizophrenia spectrum disorder, psychotic disorder, bipolar
disorder type I \& II, cluster B personality disorders (antisocial, borderline, narcissistic, histrionic),
eating disorders, as defined by the DSM-5-TR~6. Participation in other clinical studies involving
neuropsychological measures being collected more than one time per year.~7. Reported use of other drugs
(cocaine, opiates, methamphetamine, MDMA) in the past 60 days or test positive on a urine test for those drugs
of abuse at baseline.~8. Report using cannabis, including products with or without CBD, more than four times
per month.~9. Recent history of, or meets criteria for major depression with suicidal ideation.~10. Reports use
of medical CBD.~11. Liver function enzymes (AST, ALT) that are greater than 2x normal.~12. Currently taking
medications known to be contraindicated with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate,
lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide, clobazam, lamotrigine,
valproate).~13. Pregnant at the time of study enrollment or unwilling to use contraception through the duration
of the study (if not yet post-menopausal)~14. Individuals with potentially reversible causes of mild cognitive
impairment (hypothyroidism, Vitamin B12 deficiency).
